Abciximab administration and outcome after intracoronary stent implantation

American Journal of Cardiology

Volumn 82, Issue 6 A, 1998, Pages 705-709

  Hasdai, David ^a   Rihal, Charanjit S ^a   Bell, Malcolm R ^a   Berger, Peter B ^a   Grill, Diane E ^a   Garratt, Kirk N ^a   Holmes Jr , David R ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; DEXTRAN; DIPYRIDAMOLE; ENOXAPARIN; HEPARIN; TICLOPIDINE; WARFARIN;

ADULT; AGED; ARTERY CALCIFICATION; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DILATATION; DEATH; DISEASE ASSOCIATION; FEMALE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HIGH RISK PATIENT; HUMAN; HYPERTENSION; INTERMETHOD COMPARISON; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PATIENT SELECTION; PRIORITY JOURNAL; SAPHENOUS VEIN GRAFT; STENT; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBUS; TREATMENT OUTCOME;

AGED; ANTIBODIES, MONOCLONAL; ANTICOAGULANTS; BLOOD VESSEL PROSTHESIS IMPLANTATION; CORONARY ANGIOGRAPHY; CORONARY DISEASE; CORONARY THROMBOSIS; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; STENTS; TREATMENT OUTCOME;

EID: 0032530523     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(98)00445-7     Document Type: Article

References (22)

1. Hasdai D, Berger PB, Bell MR, Rihal CS, Garratt KN, Holmes DR Jr. The changing face of coronary interventional practice: The Mayo Clinic experience. Arch Intern Med 1997;157:677-682.
2. Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 1995;332:1553-1559.
3. The EPIC investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956-961.
4. The CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet 1997;349:1429-1435.
5. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689-1696.
6. Holmes DR Jr. Technical aspects. In: Vlietstra RE, Holmes DR Jr, eds. PTCA, Percutaneous Transluminal Coronary Angioplasty. Philadelphia, PA: FA Davis Company, 1987:35-48.
7. Cannon AD, Roubin GS. The Gianturco-Roubin stent. In: Topol EJ, ed. Textbook of Interventional Cardiology. 2nd ed. Philadelphia, PA: WB Saunders Company, 1994:712-726.
8. Ellis SE. The Palmaz-Schatz stent. In: Topol EJ, ed. Textbook of Interventional Cardiology. 2nd ed. Philadelphia, PA: WB Saunders Company, 1994:702-711.
9. Lincoff AM, Tcheng JE, Califf RM, Bass T, Pompa JJ, Teirstein PS, Kleiman NS, Hattel LJ, Anderson HV, Ferguson JJ, Cabot CF, Anderson KM, Berdan LG, Musco MH, Weisman HF, Topol EJ, for the PROlog Investigators. Standard versus low-dose weight-adjusted heparin in patients treated with the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (cfE3 Fab) during percutaneous coronary revascularization. Am J Cardiol 1997;79:286-291.
10. Petula SM, Hudacek S. The FemoStop compression device: utilization guidelines for the critical care nurse. Dimensions Crit Care Nursing 1995;14: 259-264.
11. Schuhlen H, Hadamitzky M, Walter H, Ulm K, Schomig A. Major benefit from antiplatelet therapy for patients at high risk for adverse cardiac events after coronary Palmaz-Schatz stent placement. Analysis of a prospective risk stratification protocol in the Intracoronary Stenting and Antithrombotic Regimen (ISAR) Trial. Circulation 1997;95:2015-2021.
12. Ryan TJ, Bauman WB, Kennedy JW, Kereiakes DJ, King SB III, McCallister BD, Smith SC, Ullyot DJ. Guidelines for percutaneous transluminal coronary angioplasty. A report of the American Heart Association/American College of Cardiology Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Committee on Percutaneous Transluminal Coronary Angioplasty). Circulation 1993;88:2987-3007.
13. Chesebro JH, Knatterud G, Roberts R, Borer J, Cohen LS, Dalen J, Dodge HT, Francis CK, Hillis D, Ludbrook P, Markis JE, Mueller H, Passamani ER, Powers ER, Rao AK, Robertson T, Ross A, Ryan TJ, Sobel BE, Willerson J, Williams DO, Zaret BL, Braunwald E. Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Circulation 1987;76:142-154.
14. Rosenbaum PR, Rubin DB. Constructing a control group using multivariate matched sampling methods that incorporate the propensity score. American Stat 1985;39:33-35.
15. Schorr K. Antiplatelet drugs. A comparative review. Drugs 1995;50:7-28.
16. Goods CM, al-Shaibi KF, Liu MW, Yadav JS, Mathur A, Jain SP, Dean LS, Iyer SS, Parks JM, Roubin GS. Comparison of aspirin alone versus aspirin plus ticlopidine after coronary artery stenting. Am J Cardiol 1996;78:1042-1044.
17. Splawinska B, Kuzniar J, Malinga K, Mazurek AP, Splawinski J. The efficacy and potency of antiplatelet activity of ticlopidine is increased by aspirin. Int J Clin Pharmacol Ther 1996;34:352-356.
18. Herbert JM, Bernat A, Samama M, Maffrand JP. The antiaggregating and antithrombotic activity of ticlopidine is potentiated by aspirin in the rat. Thromb Haemost 1996;76:94-98.
19. Sasaki Y, Ishii I, Giddings JC, Yamamoto J. Protective effects of ticlopidine and aspirin, administered alone and in combination, on thrombus formation in rat cerebral vessels. Haemostasis 1996;26:150-156.
20. Neumann FJ, Gawaz M, Dickfeld T, Wehinger A, Walter H, Blasini R, Schomig A. Antiplatelet effect of ticlopidine after coronary stenting. J Am Coll Cardiol 1997;29:1515-1519.
21. Schomig A, Neumann FJ, Kastrati A, Schuhlen H, Blasini R, Hadamitzky M, Walter H, Zitzmann-Roth EM, Richardt G, Alt E, Schmitt C, Ulm K. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996;334:1084-1089.
22. The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 1997;96:1445-1453.